

Curriculum vitae

Surname:

First name:

Sex: Female

Date of birth:

Place of birth:

Nationality: Italian

Work address:

Policlinico Umberto I
Viale del Policlinico 155, 00161 Rome, Italy

Telephone (hospital):

Mobile phone:

E-mail:

Profession: Medical Doctor

Education: Classical Secondary High School in 1982

Basic Medical Degree (104/110) at University of Rome “La
Sapienza” in 17/03/1995

Specialization in Tropical medicine (70/70 e lode) at
University of Rome “La Sapienza” in 01/12/2006

PhD in Infectious and Tropical Medicine at University of Rome” La
Sapienza” in 31/05/ 2010

Working experiences:

Experience in clinical Phase II and III studies in GCP

2002

Contract of coordinated collaboration and continuous in the Hospital "Lazzaro Spallanzani" of Rome, related to the project of search from the title "molecular Epidemiology in the Illnesses natural infectious-resistance to HCV". During such period she is dealt besides with the study: G-S-00-952 Gilead Sciences: " To phase III b open label clinical study to evaluate safety of Tenofovir Disopropil Fumarate (Tenofovir DF) in the treatment of HIV infected patients who have limited treatment options".

2003

Contract of occasional collaboration in the Hospital "Lazzaro Spallanzani", in Rome related to the project of search "Standardization of therapeutic strategies and control in the time in the HIV-positive patient with chronic infection in treatment ".

Contract of coordinated collaboration and continuous in 2003 in the hospital " Lazzaro Spallanzani" to Rome, related to the project of search from the title" Role of new indicative molecular of the HCC in cirrhosis in relationship to the effectiveness of the different therapeutic approaches". During such period she is dealt besides with the study: "Multicenter open label early access program of Enfuvirtide (T-20/Ro 29-9800, HIV-1 fusion inhibitor) in combination with free choice antiviral regiment in patients with advanced HIV-infection. "

2010

Collaboration contract at the "Policlinico Umberto I hospital in Rome, on the Iceberg research project:" The natural history of chronic epatitis B infection: observational study of asymptomatic HBsAg carriers ".

2012

Professional collaboration contract for self-employment at the “Policlinico Umberto I hospital in Rome, relating to the research project:“ management of chronic liver diseases ”.

During this period she took care of the following studies:

“Long-term follow-up for subjects who participated in a clinical trial, in which asunaprevir (BMS-650032) and / or daclatasvir (BNS-790052) were administered for the treatment of chronic HCV hepatitis.

"Randomized Phase III Study to Evaluate the Effectiveness and Tolerability of TMC435 Vs. telaprevir, both combined with PegIFNa-2 and ribavirin, in patients with chronic HCV hepatitis, genotype 1, who had no or partial response to PegIFN and ribavirin therapy. "

2016

Professional collaboration contract for self-employment at the “Policlinico Umberto I hospital in Rome, related to the research project:“ prevalence of hepatopathy diagnosed by elastographic examination, in asymptomatic carriers of HBsAg, not treated, in presence or in absence of biochemical signs indicative of liver disease.”

2017

Contract for professional collaboration in self-employment at the “Policlinico Umberto I hospital in Rome, relating to the research project:” Identification of the various causes of development of C-virus resistance, in order to improve therapeutic treatment opportunities for patients. "

2018

Contract for professional collaboration in self-employment, at the "Policlinico Umberto I hospital in Rome, relating to the research project:" correlation between chronic HCV infection and lipid metabolism ".

During this period, she took care of the study:

"Randomized multicenter study, to study efficacy, tolerability and safety of LFN452, in patients with non-alcoholic hepatitis (NASH).

2019

Professional collaboration contract of self-employment at the Department of Translational and Precision Medicine of the "Sapienza" University of Rome relating

to the "Analysis of changes in serum lipids in patients with chronic HCV hepatitis, during therapy with antiviral action direct (DAA) ".

2020-2021

Research grant at the Department of Translational and Precision Medicine of the University of Rome "La Sapienza" related to the research project entitled : " Evaluation of the impact of HCV clearance obtained by direct antiviral drugs on the quality of life and emotional intelligence in subject with chronic hepatitis C.

During this period, she took care of the study:

A phase 2b, multicenter, double-blind, active-controlled, randomized study to investigate the efficacy and safety of different combination regimens including JNJ-73763989 and / or JNJ-56136379 for the treatment of chronic hepatitis B virus infection.

A randomized, double-blind, placebo-controlled phase 2b study to evaluate efficacy pharmacokinetics and safety of 48-week study intervention with JNJ-73763989+JNJ-561363379+nucleos(t)ide analog(NA) regimen compared to NA alone in e Antigen-negative

virologically suppressed participants with chronic hepatitis B virus infection.

2021-2022

Research grant at the Department of Translational and Precision Medicine of the University of Rome “La Sapienza” related to the research project entitled :” Evaluation of the impact of HCV clearance obtained by direct antiviral drugs on the quality of life and emotional intelligence in subject with chronic hepatitis C.

During this period, she took care of the study:

Phase 2 open label study to evaluate the safety, efficacy, pharmacodynamic, tolerability of a combination of JNJ-73763989, nucleos(t)ide analogues and a PD-1 inhibitor in patients with chronic hepatitis.

2022-2023

Research grant at the Department of Translational and Precision Medicine of the University of Rome “La Sapienza” related to the research project entitled :” Evaluation of the impact of HCV clearance obtained by direct antiviral drugs on the quality of life and emotional intelligence in subject with chronic hepatitis C.

During this period, she took care of the study:

A phase 2, Multicenter, Randomized, Double-blind, Placebo controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B and Hepatitis D Virus.

A phase 2 open-label trial evaluate safety, efficacy, tolerability and pharmacodynamics of a combination of JNJ-73763989, nucleos(t)ide analogs and a PD-1inhibitor in chronic hepatitis b patients.

Language knowledge:

- English

I authorized the treatment of my personal data in agreement with D.L. 196/2003

Rome 17/05/2023

Publications

1. LERI O., TUBILI S., SINOPOLI M.T., PUGLIESE S., PERINELLI P., DE LUCA D.:
“Epatite cronica attiva autoimmune ed anti HCV positività : descrizione di un caso”. II
Congresso Nazionale Infettivologia Civile e Militare Roma CNR 24-27 ottobre 1994
Abstract Book p.159
2. DE LUCA D., LERI O., PERINELLI P., SINOPOLI M.T., TUBILI S., PUGLIESE S.:
“Hepatitis C virus antibodies and HCV-RNA in a patient with porphyria cutanea
tarda”*Mediterranean Journal of Infectious and Parasitic diseases*“ (indexed by *Exerpta
medica and Medicine data Base*). 1995; X: 59-61
3. DE LUCA D., LERI O., CACCAVO D., FERRI G.M., AFELTRA A., PERINELLI P.:
“Anti-TNF-alfa antibodies are not associated with *Helicobacter Pylori* induced gastritis”.*Eur
Rev Med and Pharmacol Sc* 1997; 4: 1-3 (Indexed by *Index Medicus*)
4. LERI O., PERINELLI P., MASTROPASQUA M., TUBILI S., LOSI T.: “Effetti della tripla
terapia nell’eradicazione dell’*Helicobacter Pylori* : confronto tra tre diversi antibiotici”. *La
Clinica Terapeutica* (indexed by *Index Medicus*) 1997, Vol.148:Fasc.12:617-622.
5. LERI O., PERINELLI P., TUBILI S., LOSI T., MASTROPASQUA M.:“La Malaria: recenti
acquisizioni immunologiche e prospettive terapeutiche”. *La Clinica Terapeutica* (indexed
by *Index Medicus*) 1997, Vol.148: Fasc. 12:655-665.
6. LERI O., PERINELLI P., LOSI T., TUBILI S., PERI C., DE LUCA D.: “*Helicobacter
Pylori* IgG serology pattern 6-12-18 months after successfull eradication “*Mediterranean
Journal of Infectious and Parasitic diseases*” “(indexed by *Exerpta medica and Medicine
data Base*) 1997, Vol.XII-N4 157-159
7. DE LUCA D., LERI O., FIOCCA F., PERINELLI P., MASTROPASQUA M., GRASSO E.:
“Improvement of intestinal metaplasia in *Helicobacter Pylori* negative patients six month
after Misoprostol treatment”. *Eur Rev Med and Pharmacol Sc* 1998,2.:37-40

8. TOCCACELI F., PAGANNONE E., ROSATI S., IACOMI F., PERINELLI P., SCUDERI M., LAGHI V.. “ Diagnostic evaluation of hepatitis C. Present aspects and personal experience”. Mediterranean Journal of Infectious and Parasitic diseases 1998 Vol. XIII–N. 1
9. LERI O., MASTROPASQUA M., SCOPELLITI G., GRASSO E., LOSI T., IADICICCO A., PERINELLI P.: ”Effetti della terapia eradicante in pazienti affetti da gastrite cronica atrofica con sieropositività per gli anticorpi anti-HP e negatività istologica per l’*Helicobacter pylori*”. La Clinica Terapeutica 1999,150:343-346.
10. UBALDO VISCO COMANDINI, BENEDETTA LONGO, PERINELLI PAOLA, LIUZZI GIUSEPPINA, TOZZI VALERIO, ANZIDEI GIANFRANCO, ANTINORI ANDREA, IPPOLITO GIUSEPPE, GIRARDI ENRICO, MOHAMED A BUDABBUS, OSAMA A. ELIHAWI, MAHADI MEHABRESH: “ Possible child to mother transmission of HIV by breastfeeding”. Jama 2005 nov 9; 294 (18) 2301-2 16278357 (P,S,G, E, B, D)
11. SILVIA SERENO, PAOLA PERINELLI, VITTORIO LAGHI: “Changes in the prevalence of hepatitis C virus genotype among italian injection drug-users; relation to period of injection started”. J Clin vir (2009), doi: 10.106 j.jcv 2009.04.022 in press